Article
Medicine, General & Internal
E. E. Walsh, G. Perez Marc, A. M. Zareba, A. R. Falsey, Q. Jiang, M. Patton, F. P. Polack, C. Llapur, P. A. Doreski, K. Ilangovan, M. Ramet, Y. Fukushima, N. Hussen, L. J. Bont, J. Cardona, E. DeHaan, G. Castillo Villa, M. Ingilizova, D. Eiras, T. Mikati, R. N. Shah, K. Schneider, D. Cooper, K. Koury, M. -M Lino, A. S. Anderson, K. U. Jansen, K. A. Swanson, A. Gurtman, W. C. Gruber, B. Schmoele-Thoma
Summary: The RSVpreF vaccine showed efficacy in preventing RSV-associated lower respiratory tract illness and RSV-associated acute respiratory illness in adults (>= 60 years of age), with no evident safety concerns.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Immunology
Maarten J. Postma, Chih-Yuan Cheng, Nasuh C. Buyukkaramikli, Luis Hernandez Pastor, Ine Vandersmissen, Thierry Van Effelterre, Peter Openshaw, Steven Simoens
Summary: This study used a decision-tree model to estimate the impact of RSV vaccination on public health and economy in older adults in Belgium. The results demonstrated that a longer duration of vaccine protection could effectively reduce the cases and costs associated with RSV.
Article
Immunology
Yanxia Lu, Bao-Peng Liu, Crystal T. Y. Tan, Fang Pan, Anis Larbi, Tze Pin Ng
Summary: The link between pathogen exposure and mental health has been investigated in a study of over 800 participants in the Singapore Longitudinal Ageing Studies. The study found that high pathogen burden is associated with increased prevalence of depressive symptoms and impaired mental health. Certain infections and inflammatory markers were found to mediate this association. These findings highlight the potential impact of pathogens on mental health.
BRAIN BEHAVIOR AND IMMUNITY
(2022)
Article
Infectious Diseases
G. Lui, C. K. Wong, M. Chan, K. C. Chong, R. Wong, I Chu, M. Zhang, T. Li, D. S. C. Hui, N. Lee, P. K. S. Chan
Summary: This study aimed to investigate the viral kinetics, host inflammatory response, and their correlation with disease severity in older adults with RSV infection. The results showed that inflammatory cytokine IL-6 was independently associated with severe disease, while RSV viral load was not associated with disease severity.
JOURNAL OF INFECTION
(2021)
Article
Medicine, General & Internal
Shimon Amar, Yonat Shemer Avni, Norm O'Rourke, Tal Michael
Summary: The study examines the incidence rates of infectious diseases after a successful COVID-19 vaccination campaign and the lifting of social restrictions in Israel. The results suggest that the rates of respiratory and gastrointestinal infections have increased, indicating that similar trends could occur in other countries.
Article
Immunology
T. Van Effelterre, N. Hens, L. J. White, S. Gravenstein, A. R. Bastian, N. Buyukkaramikli, C. Y. Cheng, J. Hartnett, G. Krishnarajah, K. Weber, L. Hernandez Pastor
Summary: This study used a transmission model to estimate the burden of respiratory syncytial virus (RSV) in the United States. The results showed a high burden of RSV in adults aged 18 years and older, with a significant proportion in adults aged 60 years and older. Vaccinating adults aged 60 years and older could greatly reduce the disease burden in this population, as well as have indirect effects on younger adults.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Katherine M. Begley, Arnold S. Monto, Lois E. Lamerato, Anurag N. Malani, Adam S. Lauring, H. Keipp Talbot, Manjusha Gaglani, Tresa McNeal, Fernanda P. Silveira, Richard K. Zimmerman, Donald B. Middleton, Shekhar Ghamande, Kempapura Murthy, Lindsay Kim, Jill M. Ferdinands, Manish M. Patel, Emily T. Martin
Summary: In this study, adults hospitalized with respiratory syncytial virus (RSV) were found to have worse outcomes compared with influenza. They were more likely to have cardiopulmonary comorbidities, experience a longer stay, and require mechanical ventilation. This study highlights the importance of RSV surveillance and informs future vaccination strategies.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Immunology
Yingcheng Wang, Ginenus Fekadu, Joyce H. S. You
Summary: This study evaluates the cost-effectiveness of AREXVY (R) and ABRYSVO (R) in Hong Kong and finds that a single dose of either vaccine can increase quality-adjusted life-years for older adults over a period of 2 years. The economic benefits of the vaccines are influenced by the vaccine price and RSV attack rate.
Article
Immunology
F. Zeevat, J. Luttjeboer, J. H. J. Paulissen, J. van der Schans, P. Beutels, C. Boersma, M. J. Postma
Summary: This study aimed to explore the cost-effectiveness of RSV infection in older adults and conducted surveys in the Netherlands and the United Kingdom. The results showed that RSV vaccination could be cost-effective in both countries, depending on the specific RSV incidence, vaccine effectiveness, and price.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Joseph A. Lewnard, Katia J. Bruxvoort, Vennis X. Hong, Lindsay R. Grant, Luis Jodar, Alejandro Cane, Bradford D. Gessner, Sara Y. Tartof
Summary: PCV13 conferred moderate protection against virus-associated lower respiratory tract infections. The vaccine displayed a 24.9% effectiveness against virus-associated pneumonia and a 21.5% effectiveness against other virus-associated lower respiratory tract infections. The study also found statistically significant protection against LRTI episodes associated with influenza A and B viruses, endemic human coronaviruses, parainfluenza viruses, human metapneumovirus, and enteroviruses but not respiratory syncytial virus or adenoviruses.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
James Baber, Mark Arya, Yuben Moodley, Anna Jaques, Qin Jiang, Kena A. Swanson, David Cooper, Mohan S. Maddur, Jakob Loschko, Alejandra Gurtman, Kathrin U. Jansen, William C. Gruber, Philip R. Dormitzer, Beate Schmoele-Thoma
Summary: The stabilized RSV prefusion F subunit (RSVpreF) vaccine candidate was well tolerated and elicited strong and persistent serum neutralizing responses in adults aged 65-85, with or without adjuvant. Adjuvanted formulations did not show additional enhancement of immune responses.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Immunology
Eugene Athan, James Baber, Karen Quan, Robert J. Scott, Anna Jaques, Qin Jiang, Wen Li, David Cooper, Mark W. Cutler, Elena Kalinina, Annaliesa S. Anderson, Kena A. Swanson, William C. Gruber, Alejandra Gurtman, Beate Schmoele-Thoma
Summary: This study demonstrates the noninferiority of immune responses with coadministration of RSVpreF and SIIV in an older-adult population, and shows that the coadministration has an acceptable safety and tolerability profile.
CLINICAL INFECTIOUS DISEASES
(2023)
Review
Infectious Diseases
Mark H. H. Rozenbaum, Elizabeth Begier, Samantha K. K. Kurosky, Jo Whelan, Danai Bem, Koen B. B. Pouwels, Maarten Postma, Louis Bont
Summary: This article reviews the incidence and prevalence of RSV infection in older adults and adults with respiratory or cardiovascular comorbidities. It highlights the potential limitations in RSV epidemiology studies and suggests points to consider when evaluating or designing them.
INFECTIOUS DISEASES AND THERAPY
(2023)
Article
Immunology
Jason R. Gantenberg, Robertus van Aalst, Nicole Zimmerman, Brendan Limone, Sandra S. Chaves, William V. La Via, Christopher B. Nelson, Christopher Rizzo, David A. Savitz, Andrew R. Zullo
Summary: RSV is a major cause of infant hospitalization in the United States. While preterm infants and those with specific comorbidities are at high risk, 80% of RSV infections occur in term infants without comorbidities. Future prevention efforts should target all infants.
JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Medicine, General & Internal
Jocelyn Moyes, Stefano Tempia, Sibongile Walaza, Meredith L. McMorrow, Florette Treurnicht, Nicole Wolter, Anne von Gottberg, Kathleen Kahn, Adam L. Cohen, Halima Dawood, Ebrahim Variava, Cheryl Cohen
Summary: Studying the economic burden of RSV-associated illness can help inform decisions on the implementation of maternal vaccines and monoclonal antibodies. A costing study conducted in South Africa estimated the cost of RSV-associated illness in infants and found that the highest cost burden was in the youngest infants.
Article
Economics
Timothy Spelman, William L. Herring, Yuanhui Zhang, Michael Tempest, Isobel Pearson, Ulrich Freudensprung, Carlos Acosta, Thibaut Dort, Robert Hyde, Eva Havrdova, Dana Horakova, Maria Trojano, Giovanna De Luca, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Raed Alroughani, Eugenio Pucci, Franco Granella, Jeannette Lechner-Scott, Patrizia Sola, Diana Ferraro, Francois Grand'Maison, Murat Terzi, Csilla Rozsa, Cavit Boz, Raymond Hupperts, Vincent Van Pesch, Celia Oreja-Guevara, Anneke van der Walt, Vilija G. Jokubaitis, Tomas Kalincik, Helmut Butzkueven
Summary: This study compared the effectiveness and cost-effectiveness of switching to natalizumab or fingolimod for patients with highly active relapsing-remitting multiple sclerosis inadequately responding to first-line therapies. The results showed that escalating therapy to natalizumab resulted in higher quality-adjusted life-years and lower costs compared to fingolimod for UK patients.
Article
Health Care Sciences & Services
William Herring, Michael Ciarametaro, Josephine Mauskopf, David Wamble, Brian Sils, Robert Dubois
Summary: The study analyzed the impact of drug innovations on six diseases over the past 30 years, showing that without these innovations, mortality or morbidity rates for some diseases could have been higher. Experts suggest that policies should consider the pricing and value of drugs, and recognize the societal importance of the pharmaceutical industry's ability to respond quickly to emerging diseases.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
(2022)
Article
Pediatrics
Sandra E. Talbird, Justin Carrico, Elizabeth M. La, Cristina Carias, Gary S. Marshall, Craig S. Roberts, Ya-Ting Chen, Mawuli K. Nyaku
Summary: Routine childhood immunization in the United States continues to yield significant reductions in incidence across all targeted diseases. Efforts to maintain and improve vaccination coverage are necessary to continue experiencing low incidence levels of vaccine-preventable diseases. Influenza and Streptococcus pneumoniae-related acute otitis media remain the highest disease incidence rates.
Article
Pediatrics
Justin Carrico, Elizabeth M. La, Sandra E. Talbird, Ya-Ting Chen, Mawuli K. Nyaku, Cristina Carias, Claire E. Mellott, Gary S. Marshall, Craig S. Roberts
Summary: This study evaluated the economic impact of routine childhood immunization in the United States and found that in addition to reducing diseases and deaths, this immunization measure also saves costs.
Article
Clinical Neurology
Ron L. H. Handels, Colin Green, Anders Gustavsson, William L. Herring, Bengt Winblad, Anders Wimo, Anders Skoldunger, Andreas Karlsson, Robert Anderson, Mark Belger, Chiara Bruck, Robert Espinosa, Jakub P. Hlavka, Eric Jutkowitz, Pei-Jung Lin, Mauricio Lopez Mendez, Javier Mar, Peter Shewmaker, Eldon Spackman, Ali Tafazzoli, Bryan Tysinger, Linus Jonsson
Summary: This article reports on the results of the International PharmacoEconomic Collaboration on Alzheimer's Disease (IPECAD) Modeling Workshop Challenge. Participants jointly developed two common benchmark scenarios for the treatment of Alzheimer's disease and conducted model comparisons and discussions. The results showed a high level of agreement among participants, which is important for establishing transparent and credible Alzheimer's disease models.
ALZHEIMERS & DEMENTIA
(2023)
Article
Immunology
Donal Bisanzio, Ashley E. Davis, Sandra E. Talbird, Thierry Van Effelterre, Laurent Metz, Maren Gaudig, Valerie Oriol Mathieu, Anita J. Brogan
Summary: This study aimed to assess the impact of preventive vaccination strategies when implemented in conjunction with nonpharmaceutical interventions (NPI) and ring vaccination. The results showed that including healthcare workers, frontline workers, and the general population in the preventive vaccination campaign can significantly reduce Ebola cases, hospitalizations, and deaths.
Article
Economics
Xiao Li, David Hodgson, Julien Flaig, Alexia Kieffer, William L. Herring, Hadi Beyhaghi, Lander Willem, Mark Jit, Joke Bilcke, Philippe Beutels
Summary: This study compared static and dynamic models to analyze the cost-effectiveness of maternal vaccine (MV) and monoclonal antibody (mAb) interventions against respiratory syncytial virus (RSV). The static models estimated fewer medically attended cases averted, but showed significant cost savings and quality-adjusted life years (QALYs) gained. On the other hand, the dynamic models estimated more cases averted, especially non-medically attended cases. These differences can be explained by the model types and assumptions on non-medical burden and intervention effectiveness over time.
Article
Multidisciplinary Sciences
Laura T. R. Morrison, Benjamin Anderson, Alice Brower, Sandra Talbird, Naomi Buell, Pia D. M. A. MacDonald, Laurent Metz, Maren Gaudig, Valerie Oriol Mathieu, Amanda A. Honeycutt
Summary: This study evaluates the relationship between outbreak size and economic impact, finding that prophylactic vaccines can mitigate the negative economic impacts of infectious disease outbreaks. The study surveyed five countries in sub-Saharan Africa that experienced Ebola outbreaks between 2000 and 2016, and found that outbreaks led to a decline in GDP of up to 36%, which could be reduced to around 1.6% with targeted prophylactic vaccination.
Article
Immunology
Sandra E. Talbird, Seri A. Anderson, Misha Nossov, Nell Beattie, Aaron T. Rak, Francisco Diaz-Mitoma
Summary: The recently approved 3-antigen hepatitis B vaccine is cost-saving or cost-effective for preventing HBV infection among US adults. It provides better health outcomes, more quality-adjusted life-years, and lower costs compared to the single-antigen vaccine in adults aged 18-64, adults with diabetes, and adults with obesity. For adults aged >= 65 years, the 3-antigen vaccine is cost-effective below common willingness-to-pay thresholds.
Article
Public, Environmental & Occupational Health
Justin Carrico, Claire E. Mellott, Sandra E. Talbird, Andre Bento-Abreu, Barbara Merckx, Jessica Vandenhaute, Damia Benchabane, Nicolas Dauby, Olivier Ethgen, Philippe Lepage, Jeroen Luyten, Marc Raes, Steven Simoens, Marc Van Ranst, Amanda Eiden, Mawuli K. Nyaku, Goran Bencina
Summary: In this study, the public health impact and return on investment of Belgium's pediatric immunization program (PIP) were evaluated. The PIP was found to prevent infections and deaths, as well as save costs in both the healthcare sector and society. Continued investment in the PIP is recommended to sustain its positive impact.
FRONTIERS IN PUBLIC HEALTH
(2023)
Meeting Abstract
Economics
S. Talbird, J. Graham, S. Anderson, M. Nossov, N. Beattie, Lains C. Sousa, A. Rak, H. Masters, F. Diaz-Mitoma
Meeting Abstract
Economics
C. Mellott, R. Jaworski, J. Carrico, M. Clinkscales, S. Talbird, I Dobrowolska, D. Golicki, E. Tsoumani, U. Sabale
Meeting Abstract
Economics
K. Paret, H. Beyhaghi, W. Herring, M. Rousculp, S. Toback, J. Mauskopf